10 Aug 2016
Zydus Group firm Cadila Healthcare today said it has acquired Melgain lotion used for treatment of skin depigmentation from Issar Pharma to strengthen its dermatological portfolio.
In India, Melgain will be marketed by Liva Healthcare, a specialty division of the group catering to the dermatological segment.
Why Zydus acquires Melgain?
Zydus is having strong presence in Dermatology segment. This acquisition will strengthen portfolio of derma brands and will leverage our equity in this key segment. Zydus already has strong presence in the hyperpigmentation, acne, haircare and anti—fungal segments, the expansion into the re-pigmentation segment gives Zydus an edge in the fast growing dermatology market which is currently growing at 14 per cent and valued at over Rs. 6,000 crore. (In Indian Market)
Zydus may launch this product in other global markets where it is not available.
Melgain is used for the treatment of Vitiligo, a chronic skin condition characterized by portions of the skin losing their pigment. It occurs when skin pigment cells die or are unable to function. Though the reason for the onset of the condition is not known, the most widely accepted view is that the depigmentation occurs because Vitiligo is an autoimmune disease – a disease in which a person’s immune system reacts against the body’s own organs or tissues.